136 related articles for article (PubMed ID: 17513819)
1. Proposal for the use of progression-free survival in unblinded randomized trials.
Freidlin B; Korn EL; Hunsberger S; Gray R; Saxman S; Zujewski JA
J Clin Oncol; 2007 May; 25(15):2122-6. PubMed ID: 17513819
[TBL] [Abstract][Full Text] [Related]
2. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.
Bhattacharya S; Fyfe G; Gray RJ; Sargent DJ
J Clin Oncol; 2009 Dec; 27(35):5958-64. PubMed ID: 19826121
[TBL] [Abstract][Full Text] [Related]
3. Recommendations for the assessment of progression in randomised cancer treatment trials.
Dancey JE; Dodd LE; Ford R; Kaplan R; Mooney M; Rubinstein L; Schwartz LH; Shankar L; Therasse P
Eur J Cancer; 2009 Jan; 45(2):281-9. PubMed ID: 19097775
[TBL] [Abstract][Full Text] [Related]
4. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
[TBL] [Abstract][Full Text] [Related]
5. Assessing temporal agreement between central and local progression-free survival times.
Zeng D; Cornea E; Dong J; Pan J; Ibrahim JG
Stat Med; 2015 Feb; 34(5):844-58. PubMed ID: 25393731
[TBL] [Abstract][Full Text] [Related]
6. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
[TBL] [Abstract][Full Text] [Related]
7. Optimizing randomized phase II trials assessing tumor progression.
Stone A; Wheeler C; Carroll K; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
[TBL] [Abstract][Full Text] [Related]
8. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.
Amit O; Mannino F; Stone AM; Bushnell W; Denne J; Helterbrand J; Burger HU
Eur J Cancer; 2011 Aug; 47(12):1772-8. PubMed ID: 21429737
[TBL] [Abstract][Full Text] [Related]
9. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
10. Blinded and unblinded internal pilot study designs for clinical trials with count data.
Schneider S; Schmidli H; Friede T
Biom J; 2013 Jul; 55(4):617-33. PubMed ID: 23703749
[TBL] [Abstract][Full Text] [Related]
11. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.
Sridhara R; Mandrekar SJ; Dodd LE
Clin Cancer Res; 2013 May; 19(10):2613-20. PubMed ID: 23669421
[TBL] [Abstract][Full Text] [Related]
12. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?
Dodd LE; Korn EL; Freidlin B; Jaffe CC; Rubinstein LV; Dancey J; Mooney MM
J Clin Oncol; 2008 Aug; 26(22):3791-6. PubMed ID: 18669467
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of three definitions of progression-free survival in preoperative cancer therapy (JCOG0801-A).
Nakamura K; Shibata T; Takashima A; Yamamoto S; Fukuda H
Jpn J Clin Oncol; 2012 Oct; 42(10):896-902. PubMed ID: 22844128
[TBL] [Abstract][Full Text] [Related]
14. [Health related quality of life and endpoints in oncology].
Bonnetain F
Cancer Radiother; 2010 Oct; 14(6-7):515-8. PubMed ID: 20674446
[TBL] [Abstract][Full Text] [Related]
15. Model free audit methodology for bias evaluation of tumour progression in oncology.
Stone A; Macpherson E; Smith A; Jennison C
Pharm Stat; 2015; 14(6):455-63. PubMed ID: 26435269
[TBL] [Abstract][Full Text] [Related]
16. New challenges for comparative effectiveness in oncology: choice of primary end points for randomized clinical trials.
Freidlin B; Abrams JS; Korn EL
J Comp Eff Res; 2013 Sep; 2(5):469-81. PubMed ID: 24236744
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
[TBL] [Abstract][Full Text] [Related]
18. Joint modeling of progression-free survival and death in advanced cancer clinical trials.
Dejardin D; Lesaffre E; Verbeke G
Stat Med; 2010 Jul; 29(16):1724-34. PubMed ID: 20572123
[TBL] [Abstract][Full Text] [Related]
19. Testing of evaluation bias for progression free survival endpoint in oncology clinical trials.
Sun Y; Wu W; Sargent D
Stat Med; 2016 Sep; 35(22):3923-32. PubMed ID: 27089832
[TBL] [Abstract][Full Text] [Related]
20. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
Galsky MD; Krege S; Lin CC; Hahn N; Ecke T; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
Cancer; 2013 Aug; 119(16):3020-6. PubMed ID: 23720197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
